Jul 06, 2011
Cambrex Corporation and Tillotts Pharma AG are pleased to announce they have entered into a development and commercialization agreement for a proprietary mesalamine-based (5-ASA) technology for use in the treatment of Inflammatory Bowel Disease (IBD).
“This deal, which gives Tillotts worldwide access to an exciting proprietary 5-ASA-based technology, is an additional important step in our forceful efforts over the years to come to build an attractive and innovative gastrointestinal product portfolio, complementary to our Asacol® and Colpermin®,” commented Thomas A. Tóth von Kiskér, President and CEO of Tillotts.
Download full press release.